Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Jae Hyun | - |
dc.contributor.author | Park, Eun-Gee | - |
dc.contributor.author | Kim, Sunhee | - |
dc.contributor.author | Kim, Sin Gon | - |
dc.contributor.author | Hahn, Seokyung | - |
dc.contributor.author | Kim, Nam Hoon | - |
dc.date.accessioned | 2021-09-01T06:51:57Z | - |
dc.date.available | 2021-09-01T06:51:57Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2019-09-10 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/62890 | - |
dc.description.abstract | This study was conducted to investigate the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on individual renal outcomes in patients with type 2 diabetes. We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from inception to September 2017 to identify randomized controlled trials comparing SGLT2 inhibitors with placebo or antidiabetic drugs and reporting any renal outcomes in patients with type 2 diabetes. Additionally, we identified 4 articles which were published after the predefined period to include relevant data. A meta-analysis was performed to calculate weighted mean differences (WMDs) and relative risks (RRs) with 95% confidence intervals (Cis) for each renal outcome. We included 48 studies involving 58,165 patients in the analysis. SGLT2 inhibitors significantly lowered urine al bumin-to-creatinine ratio (UACR) (WMD, - 14.64 mg/g; 95%CI, -25.15 to -4.12; P= 0.006) compared with controls. The UACR-lowering effects of SGLT2 inhibitors were greater with a higher baseline UACR. Overall changes in estimated glomerular filtration rate (eGFR) were comparable between two groups (WMD, 0.19 mL/min/1.73 m(2); 95%CI, - 0.44 to 0.82; P= 0.552). However, SGLT2 inhibitors significantly slowed eGFR decline in patients with a higher baseline eGFR and a longer duration of treatment. Compared with controls, SGLT2 inhibitors significantly reduced the risk of microalbuminuria (RR, 0.69; 95%CI, 0.49 to 0.97; P= 0.032), macroalbuminuria (RR, 0.49; 95%CI, 0.33 to 0.73; P < 0.001), and worsening nephropathy (RR, 0.73; 95% CI, 0.58 to 0.93; P= 0.012). In addition, the risk of end-stage renal disease was significantly lower in SGLT2 inhibitors than in controls (RR, 0.70; 95% CI, 0.57 to 0.87; P= 0.001). In conclusion, SGLT2 inhibitors had beneficial renal effects by lowering the risk of albuminuria development or progression and reducing the risk of end-stage renal disease compared with placebo or other antidiabetic drugs. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject | ADD-ON THERAPY | - |
dc.subject | INADEQUATE GLYCEMIC CONTROL | - |
dc.subject | LONG-TERM EFFICACY | - |
dc.subject | DAPAGLIFLOZIN REDUCES ALBUMINURIA | - |
dc.subject | METFORMIN PLUS SULFONYLUREA | - |
dc.subject | CARDIOVASCULAR RISK-FACTORS | - |
dc.subject | CHRONIC KIDNEY-DISEASE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | INITIAL COMBINATION | - |
dc.subject | BLOOD-PRESSURE | - |
dc.title | Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Sin Gon | - |
dc.contributor.affiliatedAuthor | Kim, Nam Hoon | - |
dc.identifier.doi | 10.1038/s41598-019-49525-y | - |
dc.identifier.scopusid | 2-s2.0-85072018442 | - |
dc.identifier.wosid | 000484986300023 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.9 | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | ADD-ON THERAPY | - |
dc.subject.keywordPlus | INADEQUATE GLYCEMIC CONTROL | - |
dc.subject.keywordPlus | LONG-TERM EFFICACY | - |
dc.subject.keywordPlus | DAPAGLIFLOZIN REDUCES ALBUMINURIA | - |
dc.subject.keywordPlus | METFORMIN PLUS SULFONYLUREA | - |
dc.subject.keywordPlus | CARDIOVASCULAR RISK-FACTORS | - |
dc.subject.keywordPlus | CHRONIC KIDNEY-DISEASE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | INITIAL COMBINATION | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.